Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,332 shares of the life sciences company’s stock after selling 3,998 shares during the period. Handelsbanken Fonder AB’s holdings in Illumina were worth $7,008,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Van ECK Associates Corp lifted its stake in Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock valued at $20,347,000 after acquiring an additional 22,718 shares during the period. Strategic Financial Concepts LLC acquired a new position in shares of Illumina in the 4th quarter valued at $1,464,000. Allworth Financial LP lifted its stake in shares of Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after purchasing an additional 6,263 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Illumina in the 4th quarter valued at $448,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Illumina by 0.8% in the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock valued at $454,617,000 after purchasing an additional 27,618 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Illumina stock opened at $88.13 on Friday. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The firm has a market capitalization of $13.95 billion, a price-to-earnings ratio of -11.48, a PEG ratio of 1.60 and a beta of 1.32. The company has a fifty day simple moving average of $78.75 and a 200-day simple moving average of $103.31. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the prior year, the firm earned $0.98 earnings per share. The company’s revenue for the quarter was down 1.4% compared to the same quarter last year. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Transactions at Illumina

In other news, CFO Ankur Dhingra acquired 6,100 shares of the company’s stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the acquisition, the chief financial officer now owns 24,906 shares of the company’s stock, valued at $2,022,616.26. This trade represents a 32.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.60% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ILMN shares. Piper Sandler decreased their target price on shares of Illumina from $190.00 to $185.00 and set an “overweight” rating for the company in a research note on Thursday, May 15th. Guggenheim decreased their target price on shares of Illumina from $122.00 to $114.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. Morgan Stanley decreased their target price on shares of Illumina from $136.00 to $100.00 and set an “equal weight” rating for the company in a research note on Monday, May 12th. Finally, Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $126.94.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.